Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation

A Patient With Metastatic Lung Adenocarcinoma Harboring ConcurrentEGFRL858R,EGFRGermline T790M, andPIK3CAMutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer

(2017) Philip E. Lammers et al.   Journal of the National Comprehensive Cancer Network

Targeting PI3 kinase in cancer

(2015) Todd M. Bauer et al.   PHARMACOLOGY & THERAPEUTICS

Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis

(2014) Roch-Philippe Charles et al.   MOLECULAR CANCER RESEARCH

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

(2014) L. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma

(2014) Marian M. Deuker et al.   Cancer Discovery

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase

(2013) Hashem A. Dbouk et al.   PLoS One

Visualizing multidimensional cancer genomics data

(2013) Michael P Schroeder et al.   Genome Medicine

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives

(2013) Joy Tang et al.   Frontiers in Pharmacology

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

(2011) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer

(2011) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

(2011) Takayuki Kosaka et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

(2011) Matthew T. Burger et al.   ACS Medicinal Chemistry Letters

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Erlotinib Induces Mitochondrial-Mediated Apoptosis in Human H3255 Non-Small-Cell Lung Cancer Cells with Epidermal Growth Factor ReceptorL858R Mutation through Mitochondrial Oxidative Phosphorylation-Dependent Activation of BAX and BAK

(2008) Y.-H. Ling et al.   MOLECULAR PHARMACOLOGY

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE